242 results about "Respiratory tract" patented technology

The present application provides a snoring treatment device, including a vibration part, the vibration part is provided with an opening for the inflow of exhaled airflow, an inner cavity connected to the opening, and an exhaust port connected to the inner cavity, and the vibration part is adapted to generate a vibration sound wave with a frequency range of 20 to 200 Hz under the action of the exhaled airflow after the inflow of the exhaled airflow. The snoring treatment device provided by the present application can accurately exercise the upper respiratory tract muscles, making the upper respiratory tract muscles strong, thereby achieving the purpose of treating snoring.

The invention provides a nucleic acid composition for respiratory tract pathogen detection and application thereof, and relates to the technical field of biology. The invention provides a nucleic acid detection composition which has high specificity and can be used for detecting various respiratory pathogens. The composition can be used for detecting influenza B virus, influenza A virus H1N1, influenza A virus H3N2, novel coronavirus N gene, novel coronavirus O gene, respiratory syncytial virus, I-type parainfluenza virus, II-type parainfluenza virus, III-type parainfluenza virus, IV-type parainfluenza virus, rhinovirus, adenovirus, haemophilus influenzae, and the like. The kit has 15 pathogens including streptococcus pneumoniae and staphylococcus aureus, the lower detection limit can be as low as 20 copies / reaction, and the kit plays an important role in rapid detection of respiratory tract pathogens.

A robust nasal organoid culture system and fully characterized 2D and 3D in vitro produced organoids are provided, as well as methods of using the organoids. The nasal organoids comprise a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for producing two-dimensional and three-dimensional nasal organoids are also provided. These methods generally require a two-phase culture system, i.e., amplification and differentiation culture. The provided nasal organoids are suitable for reproducing nasal tissue complexity, for mimicking respiratory diseases, studying barrier function and drug delivery, high throughput drug screening, and assessing the effects of pathogens and environmental toxins on nasal respiratory epithelium.

The present application provides a snoring treatment device, comprising a vibration part, the vibration part is provided with an opening for the inflow of exhaled airflow, an inner cavity connected to the opening, and an exhaust port connected to the inner cavity, and the vibration part is adapted to generate a vibration sound wave with a frequency range of 20 to 200 Hz under the action of the exhaled airflow after the inflow of the exhaled airflow. The snoring treatment device provided by the present application can accurately exercise the upper respiratory tract muscles, making the upper respiratory tract muscles strong, thereby achieving the purpose of treating snoring.

The invention provides a probe set and method for detecting respiratory tract infection pathogenic microorganisms and application of the probe set and method. The probe group is high in specificity and sensitivity, capable of accurately capturing target species in a pathogen spectrum and efficiently enriching the target species, meanwhile, few library fragments of non-target species are introduced, pathogenic microorganisms are convenient to identify, the detection sensitivity is high, the accuracy is good, the time cost is saved, the coverage degree is wide, and the application prospect is wide. Various bacteria, fungi, viruses and other pathogenic microorganisms related to respiratory tract infection can be covered.

The invention relates to a model training method and a respiratory tract infection pathogen identification method and system, and the method comprises the steps: obtaining the clinical data of a respiratory tract infection pathogen; preprocessing the clinical data to obtain a training set; training a respiratory tract infection pathogen recognition model by using the training set to obtain the trained respiratory tract infection pathogen recognition model; wherein the trained respiratory tract infection pathogen identification model is used for identifying the respiratory tract infection pathogen based on the index detection data of the respiratory tract infection pathogen. Compared with the prior art, the method has the advantages of good recognition effect, low sampling requirement, high treatment efficiency and the like.

The invention discloses a nucleic acid combination product, a kit and a method for detecting various respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-SEQ ID NO: 24. The nucleic acid combination product realizes synchronous detection of various pathogens through a one-tube eight-color fluorescent PCR, freeze-drying and ultrasonic direct diffusion method technology, significantly reduces experimental operation steps, shortens detection time, reduces the complexity of result interpretation, and has strong anti-interference capability and high sensitivity.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention provides an upper respiratory tract muscle group mechanical property measuring and evaluating method based on signal characteristics. Firstly, a force signal of an upper respiratory tract muscle group is collected through a sensor; after the signals are subjected to voltage amplification filtering and digital processing, key characteristic variables including the maximum muscle force, the muscle force stability, the total acting amount, the fatigue index and the overall testing time are generated. In order to improve the evaluation accuracy, a multi-level machine learning model is introduced, and the multi-level machine learning model comprises a basic TabTransform structure, a contrast learning framework and a meta-learning technology so as to realize deep analysis of a feature complex interaction relationship. In the model training process, through comparative learning of unlabeled data, the feature representation capability is enhanced; an MAML framework is adopted to quickly adapt to a small amount of labeled data, and a comprehensive target of disease grading and curative effect prediction is taken into account by utilizing a multi-task learning strategy. Finally, the performance index of the model on the verification set is remarkably improved, and efficient evaluation and rapid deployment can be achieved in practical application.

Provided is a mutant of a respiratory syncytial virus (RSV) pre-fusion conformational F protein. The mutant comprises an amino acid mutation relative to the amino acid sequence of a wild-type RSV F protein, the amino acid mutation being amino acids at a position 392 and a position 493 or a position near the position 493 being substituted by C, and a disulfide bond being formed between a position 392C and a position 493C or a position near the position 493C after the mutation. Also provided are a related DNA coding sequence, recombinant plasmid and mRNA sequence and a corresponding RSV vaccine. By introducing a disulfide bond at a suitable position, and combining same with cavity filling, electrostatic mutation, proline mutation and the like, the expression and stability of an F protein having pre- and post-fusion conformations and a trimerized conformation are significantly improved, and the conformation of the F protein is significantly inhibited from being converted into the post-fusion conformation. The mutant is also applied to preparation of an RSV vaccine and RSV infection detection.

The invention belongs to the technical field of biological medicine, and relates to application of an OXTR agonist in preparation of a medicine for treating chronic sinusitis (CRS) and respiratory ciliary injury. CRS is treated based on targeted OXTR, and it is found that the OXTR agonist has an excellent treatment effect on promotion of nasal mucosa cilia regeneration and improvement of chronic sinusitis and can promote cilia repair, reduce infiltration of neutrophils and eosinophils and improve the inflammatory environment. In addition, an intranasal treatment dosage form aiming at OXTR is already applied to clinical application of nervous system diseases, the clinical application range of the medicine is expanded, practical feasibility is achieved by improving a better dosage form, and good industrialization prospects are achieved.

A hydrogel composition for intranasal delivery of an antifungal (amphotericin B) at an infection site, specifically the nasal mucosa and upper respiratory tract.

The invention belongs to the technical field of medical equipment, and particularly relates to pneumology department foreign matter forceps which comprise forceps handles, the upper ends of the forceps handles are fixedly connected with connecting blocks, forceps clips are rotationally arranged on the two sides of the upper end of a sleeve, and traction type rotating mechanisms used for adjusting the angle of foreign matter are further arranged on the forceps clips. The traction type rotating mechanism comprises a rotating block rotationally arranged on one side of the upper end of the forceps holder, and an anti-skid pad is arranged on one side of the rotating block; by means of the traction type rotating mechanism, when the foreign matter is a long-strip sharp foreign matter such as a fishbone and a pin, the foreign matter is clamped between the two rotating blocks, the rotating blocks are driven to rotate so that the foreign matter can rotate, when the foreign matter rotates, the two sharp ends of the foreign matter can be away from the inner wall of the respiratory tract till the foreign matter is parallel to the sleeve, and at the moment, the foreign matter is taken out; therefore, the condition that a patient feels uncomfortable due to the fact that the respiratory mucosa is punctured by the foreign matter in the taking-out process due to scraping between the foreign matter and the respiratory tract can be avoided.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention relates to the field of public health, in particular to an intelligent identification and real-time early warning system for unknown pathogens in respiratory tract samples of fever outpatient service, which comprises a data quality control processing module for performing quality control and standardized preprocessing on metagenome original sequencing data to obtain pure microorganism reading length; the known pathogen identification and annotation module is used for identifying known pathogens, classifying non-host reads, constructing a classification database according to a classification result, and annotating reads with low classification confidence or unclassified reads in the classification result to obtain an annotation table; the recognition model training module is used for constructing a positive and negative sample data set and training a recognition model; and the unknown pathogen identification module is used for identifying potential unknown pathogens in the metagenome of the pure microorganism read length by adopting the trained identification model according to the classification database and the annotation list. According to the invention, identification, classification and dynamic monitoring of known and unknown respiratory pathogens can be realized.

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The multi-channel laryngeal mask comprises a tube body and a mask bag connected to the tube body, and a main ventilation channel and a temperature detection channel are arranged in the tube body at intervals; a ventilation opening and a temperature detection opening are formed in the mask bag. In the using process, the mask is placed in the upper respiratory tract of a patient, the mask bag is attached to the upper end of the epiglottis of the patient to achieve sealing, and the main ventilation channel on the tube body is connected with an air source to achieve ventilation operation on the patient. The esophagus of the patient can be connected with the atmosphere through the temperature detection channel, and adverse reactions such as gaseous distention in the ventilation process are effectively prevented. Meanwhile, the body temperature detection line can extend into the temperature detection channel, partially extends out through the ventilation opening and then is inserted into the esophagus of the patient, so that relevant operations such as body temperature detection are carried out. And the imbedded instrument does not need to be frequently inserted, pulled and replaced, so that the injury to a patient caused by repeatedly switching the imbedded instrument in an operation process can be effectively avoided. In addition, the operation complexity is reduced, and the operation convenience and the operation efficiency are improved.

The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

A method for treating viral infections caused by viruses whose survival time depends on temperature (e.g., cold viruses, flu viruses, COVID-19, etc.) is based on administrating to a subject an effective amount of thermal energy transferred from a hotter liquid product to the colder subject using a predetermined combination of the temperature of the liquid product, the duration of time of supplying the liquid product, and the amount of the liquid product. This method of treatment inactivates viruses in the upper respiratory tract and gastrointestinal tract of the subject and enhances the response of the immune system, thereby preventing complications and accelerating the recovery of the infected subject.

The application discloses a nucleic acid combination product, a kit and a method for detecting multiple respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair are respectively shown as SEQ ID NO:1-SEQ ID NO:24. The nucleic acid combination product realizes the synchronous detection of multiple pathogenic bacteria through one-tube eight-color fluorescence PCR, freeze-drying and ultrasonic direct extension technology, significantly reduces the experimental operation steps, shortens the detection time, reduces the complexity of result interpretation, and has strong anti-interference ability and high sensitivity.

1. The name of the product of this design: Atomizer (compression type). 2. Purpose of this design product: This design product is used to treat upper respiratory tract diseases. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

Provided are Streptococcus salivarius and compositions comprising Streptococcus salivarius for the treatment of ENT diseases, in particular cancer therapy-induced oral mucositis and respiratory tract infections associated with cancer therapy.

In an aspect, a method for applying beta-alanine to a tissue surface is described. The method may comprise applying a composition comprising from about 0.01 % w / w to about 5.0 % w / w beta-alanine to a tissue surface. The beta-alanine may comprise between about 0.08 % w / w to about 2 % w / w. The tissue surface may be suffering from a condition. The tissue surface may be from the group consisting of epidermis, mucosal membrane, respiratory tract lining, urinary tract lining, and reproductive tract lining. In another aspect a composition may comprise from about 0.01 % w / w to about 5.0 % w / w beta-alanine; water; an emulsifying component; and a fat. The fat may be an emollient or a moisturizing component.

The utility model discloses an aerosol inhalation device convenient for tracheal intubation and tracheostomy intubation patients, which comprises an atomization medicine storage cup, an intubation connecting seat and a connecting tube, the atomization medicine storage cup is connected with the intubation connecting seat through the connecting tube, and the atomization medicine storage cup comprises a cup body and a cup cover. The lower surface of the cup cover is connected with the top end of the conical cover through a stand column and two connecting rods, a middle partition plate is arranged between the two connecting rods, drainage grooves are formed in the two sides of the inner wall of the conical cover, liquid inlet grooves are formed in the positions, located at the drainage grooves, of the bottom of the conical cover, and a sealing plug is arranged at a bypass opening in the top end of the cannula connecting base. On the premise that a trachea cannula or a tracheostomy cannula is not pulled out, a patient can inhale enough atomized liquid medicine, secretions and sputum in the respiratory tract are effectively removed, respiratory tract infection and other complications are effectively prevented, the operation of the fiberoptic bronchoscope is smoother, meanwhile, the liquid medicine can be completely pulled out, and residue and waste of the liquid medicine cannot be caused.

The present invention relates to the technical field of nanomaterials for vaccines, and particularly relates to a sepiolite in-situ grown nanozyme, a preparation method thereof and an application thereof. The preparation method is to mix ferric chloride, ethylene glycol and sodium acetate to form a suspension, and then mix sepiolite with the suspension, and react at a temperature of 180-200 °C to obtain a black precipitate. After washing and drying, sepiolite in-situ grown nanozyme is obtained. The sepiolite nanozyme realizes the in-situ growth of iron-based nanozyme on the surface of sepiolite rod-like nanostructures under hydrothermal conditions, significantly enhancing the peroxidase activity. After Sep@IONzyme is connected with inactivated influenza virus, the complex forms an appropriate positive charge distribution, enhancing the adhesion ability of the antigen to nasal mucosa. Immunizing mice with it as a nasal drop vaccine significantly improves the levels of respiratory mucosal specific sIgA antibody and serum specific IgG antibody, and can completely protect against the lethal attack of influenza virus.

Methods of treating or preventing a disease resulting from a respiratory syncytial virus (RSV) infection in a human subject is disclosed. The methods disclosed include administering to the human subject a compound of Formula (I), or pharmaceutical composition including a compound of Formula (I). In certain embodiments, the compound is celgosivir.